BNP Paribas Asset Management’s NovoCure NVCR Stock Holding History

BNP Paribas Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.97M	Sell	262,368 -247,274	-49%	-$3.74M	﹤0.01%	957
2026 Q1	$5.56M	Buy	509,642 +136,250	+36%	+$1.7M	0.01%	836
2025 Q4	$4.83M	Buy	373,392 +372,239	+32,284%	+$4.78M	0.01%	854
2025 Q3	$15K	Buy	1,153 +103	+10%	+$1.38K	﹤0.01%	1501
2025 Q2	$19K	Buy	+1,050	New	+$18.3K	﹤0.01%	1516
2023 Q3	–	Sell	-11,090	Closed	-$460K	–	856
2023 Q2	$460K	Sell	11,090 -96,306	-90%	-$5.98M	﹤0.01%	782
2023 Q1	$6.46M	Sell	107,396 -3,246	-3%	-$259K	0.02%	486
2022 Q4	$8.12M	Sell	110,642 -4,386	-4%	-$330K	0.03%	452
2022 Q3	$8.74M	Sell	115,028 -1,536	-1%	-$120K	0.03%	433
2022 Q2	$8.1M	Buy	116,564 +113,866	+4,220%	+$8.58M	0.03%	439
2022 Q1	$224K	Buy	+2,698	New	+$199K	﹤0.01%	851

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

BNP Paribas Asset Management's NVCR Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its NovoCure (NVCR) stake by 49% in Q2 2026, selling an estimated $3.74M and leaving 262,368 shares worth $3.97M. The position accounts for ﹤0.01% of the portfolio, ranked #957.

BNP Paribas Asset Management first reported a position in NVCR in Q1 2022 and has held it in 11 quarters since. The position peaked at $8.74M in Q3 2022. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

BNP Paribas Asset Management held 262,368 shares of NovoCure worth $3.97M as of Q2 2026.
BNP Paribas Asset Management sold 247,274 NovoCure shares in Q2 2026, an estimated $3.74M.
NovoCure made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #957 holding.
BNP Paribas Asset Management first reported a position in NovoCure in Q1 2022 and has held it in 11 quarters since.
BNP Paribas Asset Management's NovoCure position peaked at $8.74M in Q3 2022.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.